03:50 PM EST - Oncolytics Biotech Inc. : announced itโs in a broad preclinical and clinical collaboration with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, involving up to five, open-label, Phase 2 studies exploring the use of Reolysin in combination with chemotherapy for various cancer indications. The indications are expected to include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.06 at $1.61.
